Publication: Novel Platform Design for Screening of Optimal Immune Receptors for Antibody Circuits
No Thumbnail Available
Date
2019-05-20
Authors
Published Version
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Núñez-Báez, Sergio Gabriel. 2019. Novel Platform Design for Screening of Optimal Immune Receptors for Antibody Circuits. Master's thesis, Harvard Medical School.
Research Data
Abstract
In recent years, cancer immunotherapy has acquired a central role in the combat of cancer, an example being the use of T-cell engaging bispecific antibodies which offer a relatively simple approach to engaging patients’ T cells to target cancer cells in an HLA-independent manner. Unfortunately, trials of bispecific T-cell engaging antibodies (BiTE) have shown either severe adverse events or death that remains a major barrier to broad implementation. T cell engaging antibody circuits (TEACs) is a novel immune cell engaging platform that allows for exquisite targeting of cancer cells with minimal targeting of healthy cells. Beyond T-cells, our interest is to use this platform to engage the innate compartment. For the effective design of TEAC molecules that can redirect innate immune responses, we developed a platform that allows for dynamic screening of potential immunoreceptor targets called adaptor bispecific antibody circuits (ABA-C). It accomplishes this by using an adaptor bispecific antibody (ABA) to differentially recognize and bridge antibodies against target antigens on a cancer cell and a target immunoreceptor, emulating the synapse created by TEACs. As a model to investigate the potential of ABA-C in activating immune cells, we chose prostate adenocarcinoma as studies have linked innate immunity with its progression. Data shows that ABA-C can activate T-cells in vitro at comparable levels with TEACs in a highly specific manner at micromolar concentrations of target antigen antibody, independent of target antigen identity or cell line used. Further studies will look to use ABA-C to screen optimal activating immunoreceptors on macrophages, as their inflammatory subsets have been associated to better prognoses on prostate cancer patients.
Description
Other Available Sources
Keywords
bispecific antibodies, immunotherapy, innate immunity, antibody engineering
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service